The new approval is the first for the drug under JNJ leadership. ・The drug is also approved for the treatment of bipolar I ...

The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's drug Caplyta as an add-on ...

The J&J antipsychotic drug Caplyta won FDA approval for depression, a broader indication that could help the medicine become ...

May 18 (Reuters) - Johnson & Johnson's unit Janssen Pharmaceuticals said U.S. health regulators broadened the approval of its antipsychotic agent, Risperdal Consta, for the treatment of bipolar I ...

Electroconvulsive therapy (ECT) appears to be far more effective than algorithm-based drug therapy for treatment-resistant bipolar depression in what is believed to be the first randomized, controlled ...

The FDA is reviewing risperidone (Uzedy) extended-release injectable suspension for maintenance treatment of adults with bipolar I disorder, said makers Teva Pharmaceuticals and Medincell. The drug ...

A new study examining real-world hospital data reveals early indicators of who is most likely to benefit from Cobenfy, the ...

COPENHAGEN, Feb 18 (Reuters) - Danish pharmaceutical group Lundbeck said on Monday it would submit its drug candidate Lu AA34893 for the treatment of bipolar disorder to a 600-patient Phase II study.

Nine health bodies, including the Royal College of Psychiatrists and Royal Pharmaceutical Society, have written a letter to U.K. Secretary of State for Health and Social Care Matt Hancock MP urging ...

Each year, about 100,000 Americans experience psychosis, a serious condition that disrupts thoughts and perceptions so profoundly that it can distort a person's sense of reality.